Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

Published:2019-01-28 Issue:3 Volume:8 Page:882-889
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Fernández Montes Ana¹^ORCID,Martínez Lago Nieves²,Covela Rúa Marta³,de la Cámara Gómez Juan⁴,González Villaroel Paula⁵,Méndez Méndez José Carlos⁶,Jorge Fernández Mónica⁴,Salgado Fernández Mercedes¹,Reboredo López Margarita²,Quintero Aldana Guillermo³,Luz Pellón Augusto María⁴,Graña Suárez Begoña²,García Gómez Jesús¹

Affiliation:

1. University Hospital of Ourense Ourense Spain

2. University Hospital of A Coruña A Coruña Spain

3. Universital Hospital Lucus Augusti Lugo Spain

4. University Hospital Arquitecto Marcide Ferrol Spain

5. Oncological Center of Galicia A Coruña Spain

6. Univerity Hospital Álvaro Cunqueiro Vigo Spain

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1903

Reference23 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

3. A preclinical and clinical review of aflibercept for the management of cancer

4. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

5. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801;International Journal of Cancer;2024-08-14

2. Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI;Future Oncology;2023-12-05

3. Clinical effect and safety of targeted therapy combined with chemotherapy in the treatment of patients with advanced colon cancer;Pakistan Journal of Medical Sciences;2023-05-15

4. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation;Hypertension;2023-04

5. Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community;Clinical and Translational Oncology;2023-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3